Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 29 November 2023, 07:00 am CET Data from all three patients in non-randomized cohort treated with DSR 2.0 indicatesafe and effective maintenance of euvolemia without the need for loop diuretics,considerable benefit in cardiorenal status and dramatic improvement in diuretic response and loop diuretic requirements up to 11 weeks...
Read More
PRESS RELEASE REGULATED INFORMATION 10 November 2023, 06:00 pm CET Ids van der Weij appointed as non-executive director Ghent, Belgium – 10 November 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all...
Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 19 October 2023, 07:00 am CEST One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 months Patient preference study indicates that US patients have a strong preference for the alfapump vs large volume paracentesis[i] Matched interim analysis of patients from NACSELD[ii] registry...
Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 18 October 2023, 07:00 am CEST First two US patients from non-randomized cohort successfully treated with DSR 2.0 Initial data indicate that DSR 2.0 is safe and well tolerated, restores diuretic response and improves cardiorenal status Biomarker analysis from RED DESERT and SAHARA studies supports DSR mechanism of...
Read More
PRESS RELEASE REGULATED INFORMATION 06 October 2023, 07:00 am CEST Ghent, Belgium – 06 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend...
Read More
PRESS RELEASE REGULATED INFORMATION 4 October 2023, 06:00 pm CEST Ghent, Belgium, 4 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that, in the framework of the “restricted share unit” or “RSU” plan...
Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international liver congress / on track to file Pre-Market Approval (PMA) application to US FDA in Q4 2023 DSR® – safety of single dose DSR 2.0 demonstrated / Phase 1/2a US MOJAVE study in...
Read More
PRESS RELEASE REGULATED INFORMATION 26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed...
Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 21 June 2023, 07:00 am CEST Data presented at EASL Congress 2023 alfapump was effective in the control of ascites, virtually eliminating needle paracentesis Safety in line with expectations – particularly given disease progression in these patients – six primary safety events and limited number of key secondary...
Read More
PRESS RELEASE REGULATED INFORMATION 26 May 2023, 07:00 am CEST   Ghent, Belgium – 26 May 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to...
Read More
1 2 3 4 7

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES